These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

701 related items for PubMed ID: 18171303

  • 1. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
    Rouet F, Chaix ML, Inwoley A, Anaky MF, Fassinou P, Kpozehouen A, Rouzioux C, Blanche S, Msellati P, Programme Enfant Yopougon (Agence Nationale de Recherches sur le SIDA et les Hépatites Virales B et C 1244/1278).
    Clin Infect Dis; 2008 Feb 01; 46(3):361-6. PubMed ID: 18171303
    [Abstract] [Full Text] [Related]

  • 2. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study.
    Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F, Rouzioux C, ANRS 1236 DITRAME-B&C Study Group.
    J Med Virol; 2004 Sep 01; 74(1):34-40. PubMed ID: 15258966
    [Abstract] [Full Text] [Related]

  • 3. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P, Trabaud MA, Pradat P, Lebouché B, Chevallier M, Chevallier P, Zoulim F, Trepo C.
    Clin Infect Dis; 2007 Sep 01; 45(5):624-32. PubMed ID: 17682999
    [Abstract] [Full Text] [Related]

  • 4. Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
    N'Dri-Yoman T, Anglaret X, Messou E, Attia A, Polneau S, Toni T, Chenal H, Seyler C, Gabillard D, Wakasugi N, Eholié S, Danel C.
    Antivir Ther; 2010 Sep 01; 15(7):1029-34. PubMed ID: 21041918
    [Abstract] [Full Text] [Related]

  • 5. Relationship of CD4+ T-cell counts and plasma HIV-1 RNA levels with serological HBeAg/anti-HBe patterns obtained in West-African HBV-HIV-1-co-infected children.
    Rouet F, Chaix ML, Kpozehouen A, Inwoley A, Anaky MF, Fassinou P, Rouzioux C, Blanche S, Msellati P.
    J Trop Pediatr; 2009 Dec 01; 55(6):409-12. PubMed ID: 19447821
    [Abstract] [Full Text] [Related]

  • 6. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC, Haverkamp MH, Weersink AJ, Boucher CA, Hoepelman IM.
    Ned Tijdschr Geneeskd; 2004 Nov 20; 148(47):2330-4. PubMed ID: 15587052
    [Abstract] [Full Text] [Related]

  • 7. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.
    Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J, EuroSIDA.
    J Antimicrob Chemother; 2010 Mar 20; 65(3):548-55. PubMed ID: 20051475
    [Abstract] [Full Text] [Related]

  • 8. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital.
    Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ.
    J Med Virol; 2009 Mar 20; 81(3):406-12. PubMed ID: 19152393
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK, 903 Study Team, 907 Study Team.
    J Infect Dis; 2004 Apr 01; 189(7):1185-92. PubMed ID: 15031786
    [Abstract] [Full Text] [Related]

  • 10. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
    Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, Hung CC, Chen MY, Chang SC.
    Clin Infect Dis; 2007 Nov 01; 45(9):1221-9. PubMed ID: 17918088
    [Abstract] [Full Text] [Related]

  • 11. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ.
    J Med Virol; 2007 Nov 01; 79(11):1650-4. PubMed ID: 17854040
    [Abstract] [Full Text] [Related]

  • 12. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C, Berger A, Carlebach A, Lutz T, Bickel M, Klauke S, Staszewski S, Stuermer M.
    J Antimicrob Chemother; 2005 Dec 01; 56(6):1087-93. PubMed ID: 16269552
    [Abstract] [Full Text] [Related]

  • 13. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM.
    J Med Virol; 2007 Oct 01; 79(10):1464-71. PubMed ID: 17705185
    [Abstract] [Full Text] [Related]

  • 14. Hepatitis B virus and HIV coinfection: relationship of different serological patterns to survival and liver disease.
    Osborn MK, Guest JL, Rimland D.
    HIV Med; 2007 Jul 01; 8(5):271-9. PubMed ID: 17561872
    [Abstract] [Full Text] [Related]

  • 15. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S.
    AIDS; 2006 Oct 03; 20(15):1951-4. PubMed ID: 16988516
    [Abstract] [Full Text] [Related]

  • 16. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
    Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, Tebas P.
    J Infect Dis; 2002 Dec 15; 186(12):1844-7. PubMed ID: 12447773
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
    Hoff J, Bani-Sadr F, Gassin M, Raffi F.
    Clin Infect Dis; 2001 Mar 15; 32(6):963-9. PubMed ID: 11247719
    [Abstract] [Full Text] [Related]

  • 18. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM.
    J Viral Hepat; 2007 Mar 15; 14(3):176-82. PubMed ID: 17305883
    [Abstract] [Full Text] [Related]

  • 19. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH, Hung CC, Kao JH, Chang SY, Chen MY, Hsieh SM, Chen PJ, Chang SC.
    Clin Infect Dis; 2007 Apr 01; 44(7):988-95. PubMed ID: 17342655
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H.
    AIDS; 2008 Sep 12; 22(14):1779-87. PubMed ID: 18753861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.